Non-Alcoholic Steatohepatitis Pathogenesis: Role of Repair in Regulating the Disease Progression

被引:24
作者
Jung, Youngmi [1 ]
Diehl, Anna Mae [1 ]
机构
[1] Duke Univ, Div Gastroenterol, Durham, NC 27710 USA
关键词
Apoptosis; Liver regeneration; Fibrogenesis; Progenitors; Hedgehog; FATTY LIVER-DISEASE; IKK-BETA; HEDGEHOG; ACTIVATION; APOPTOSIS; VIABILITY; CELLS;
D O I
10.1159/000282092
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Increased hepatocyte apoptosis distinguishes non-alcoholic steatohepatitis (NASH) from non-alcoholic fatty liver disease (NAFLD). Therefore, we postulated that outcomes of NASH depended upon whether or not hepatic regenerative responses could keep pace with the increased rate of hepatocyte death. Methods: To investigate mechanisms that the liver deploys to compensate for increased hepatocyte apoptosis, we studied a transgenic mouse model in which hepatocyte vulnerability to apoptosis was increased due to disruption of NF-kappa B survival signaling. Results: We learned that hepatocyte death is coupled to the expansion of cell types that are involved in liver repair, including progenitors and myofibroblasts, and discovered that the outgrowth of these cell types occurs, at least in part, because dying hepatocytes produce Hedgehog morphogens that enhance the growth of progenitor and myofibroblast populations. The clinical significance of this discovery is supported by evidence that the degree of Hedgehog pathway activation also parallels the severity of liver fibrosis in patients with NASH, a disease in which hepatocyte apoptotic activity has been strongly linked to fibrosis progression. Conclusion: The data generated by studying a mouse model of chronic hepatocyte apoptosis, as well as NASH, a common human liver disease that is characterized by increased rates of hepatocyte apoptosis, are very similar. Both strongly support the concept that repair responses play an important role in controlling the outcomes of NASH. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:225 / 228
页数:4
相关论文
共 50 条
  • [41] PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis
    Mukhopadhyay, Partha
    Horvath, Bela
    Rajesh, Mohanraj
    Varga, Zoltan V.
    Gariani, Karim
    Ryu, Dongryeol
    Cao, Zongxian
    Holovac, Eileen
    Park, Ogyi
    Zhou, Zhou
    Xu, Ming-Jiang
    Wang, Wei
    Godlewski, Grzegorz
    Paloczi, Janos
    Nemeth, Balazs Tamas
    Persidsky, Yuri
    Liaudet, Lucas
    Hasko, Gyorgy
    Bai, Peter
    Boulares, A. Hamid
    Auwerx, Johan
    Gao, Bin
    Pacher, Pal
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (03) : 589 - 600
  • [42] Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)
    Lee, Jin Ha
    Oh, Ji Young
    Kim, Soo Hyun
    Oh, In Jeong
    Lee, Yong-ho
    Lee, Keun Woo
    Lee, Woong Hee
    Kim, Jeong-Hwan
    [J]. BIOMOLECULES, 2020, 10 (10) : 1 - 16
  • [43] Pathogenesis of non-alcoholic fatty liver disease mediated by YAP
    Chen, Ping
    Luo, Qihui
    Huang, Chao
    Gao, Qi
    Li, Like
    Chen, Jingfei
    Chen, Bing
    Liu, Wentao
    Zeng, Wen
    Chen, Zhengli
    [J]. HEPATOLOGY INTERNATIONAL, 2018, 12 (01) : 26 - 36
  • [44] Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis
    Baumann, Anja
    Jin, Cheng Jun
    Brandt, Annette
    Sellmann, Cathrin
    Nier, Anika
    Burkard, Markus
    Venturelli, Sascha
    Bergheim, Ina
    [J]. NUTRIENTS, 2020, 12 (04)
  • [45] Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats
    Noguchi, Ryuichi
    Yoshiji, Hitoshi
    Ikenaka, Yasuhide
    Kaji, Kosuke
    Shirai, Yusaku
    Aihara, Yosuke
    Yamazaki, Masaharu
    Namisaki, Tadashi
    Kitade, Mitsuteru
    Yoshii, Junichi
    Yanase, Koji
    Kawaratani, Hideto
    Tsujimoto, Tatsuhiro
    Fukui, Hiroshi
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 26 (03) : 407 - 413
  • [46] Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
    Argo, Curtis K.
    Northup, Patrick G.
    Al-Osaimi, Abdullah M. S.
    Caldwell, Stephen H.
    [J]. JOURNAL OF HEPATOLOGY, 2009, 51 (02) : 371 - 379
  • [47] Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
    Cebi, Merve
    Yilmaz, Yusuf
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [48] The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review
    Xiang, Zun
    Chen, Yi-peng
    Ma, Kui-fen
    Ye, Yue-fang
    Zheng, Lin
    Yang, Yi-da
    Li, You-ming
    Jin, Xi
    [J]. BMC GASTROENTEROLOGY, 2013, 13
  • [49] The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
    Mehta, Rohini
    Jeiran, Kianoush
    Koenig, Aaron B.
    Otgonsuren, Munkzhul
    Goodman, Zachary
    Baranova, Ancha
    Younossi, Zobair
    [J]. BMC MEDICAL GENETICS, 2016, 17
  • [50] Biochemical and molecular-genetic indicators of inflammation and apoptosis in liver cirrhosis as an outcome of the progression of non-alcoholic steatohepatitis
    Kurbatova, I. V.
    Topchieva, L. V.
    Dudanova, O. P.
    Shipovskaya, A. A.
    [J]. TERAPEVTICHESKII ARKHIV, 2019, 91 (04) : 21 - 27